Eli Lilly | LLY - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.48B 110M 2026-03
Abbott USD 11.22B 655M 2026-03
ALKERMES USD 456.48M 48.85M 2026-06
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Baxter International USD 1.86B 158M 2026-06
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Coherus Biosciences USD 18.42M 232.08M 2025-12
Drreddys Laboratories INR 123.17B 121.76B 2026-03
Eli Lilly USD 23.48B 2.3B 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.07B 137M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
J&J USD 22.54B 1.21B 2026-03
Medtronic USD 6.64B 284M 2026-03
Merck USD 12.21B 435M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novartis USD 9.85B 252M 2026-06
Novartis USD 9.6B 2.69B 2026-03
Novo Nordisk DKK 114.94B 8.68B 2026-06
Perrigo USD 697.1M 84.3M 2026-03
Pfizer USD 16.19B 19M 2026-06
Phibro Animal Health USD 215.87M 2.02M 2025-12
Prestige Brands USD 187.36M 4.56M 2026-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sanofi EUR 492M 10M 2026-06
Sanofi EUR 482M 85M 2026-03
United Therapeutics USD 310.3M 1.7M 2026-06
Zoetis USD 1.57B 65M 2026-06